Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 10/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 9/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | ATP4A | P20648 | 2/20 | 0.45 |
| ▸ | ATP4B | P51164 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28615179 | 0.78 | RAB9A (0.56) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL8346377 | 0.78 | KMT2A (0.61) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL28571840 | 0.78 | KMT2A (0.56) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL16636188 | 0.78 | KMT2A (0.56) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL5547686 | 0.78 | RAB9A (0.56) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL29683694 | 0.78 | KMT2A (0.56) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL1673852 | 0.76 | KMT2A (0.64) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL28763345 | 0.76 | NPC1 (0.50) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL69349 | 0.76 | KMT2A (0.91) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 | |
| SCHEMBL5187763 | 0.74 | RAB9A (0.51) | KMT2ARAB9AMEN1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104136431-A | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO | 2014-11-05 | — | — | CN | disclosed |
| WO-2008129129-A1 | HETEROCYCLIC PHENYL CARBAMATES AS NOVEL FAAH-INHIBITORS | KUOPION YLIOPISTO (FI) | 2008-10-30 | — | — | WO | disclosed |
| US-7354941-B2 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes | PFIZER PRODUCTS INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1252158-B1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-04-20 | — | — | EP | disclosed |
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| EP-1252158-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-1994025501-A1 | EPOXY RESINS CONTAINING THIADIAZOLE AND/OR OXADIAZOLE MOIETIES | THE DOW CHEMICAL COMPANY (US) | 1994-11-10 | — | — | WO | disclosed |
| US-3940407-A | β-Adrenergic blocking agents in the 1,2,3-thiadiazole series | SYNTEX (U.S.A.) INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186989-A1 | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | PDE4B, PDE4A, NOX4 | KMT2A 3613/4885RAB9A 1529/4885MEN1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.